| Title | Pharmacogenetic Aspects of Drug Metabolizing Enzymes and Transporters in Pediatric Medicine: Study Progress, Clinical Practice and Future Perspectives |
| Authors | Zhao, Jinxia Bian, Jialu Zhao, Yinyu Li, Yuanyuan Liu, Boyu Hao, Xu He, Shiyu Huang, Lin |
| Affiliation | Peking Univ, Dept Pharm, Peoples Hosp, 11 Xizhimen South St, Beijing 100044, Peoples R China Peking Univ, Sch Pharmaceut Sci, Dept Pharm Adm & Clin Pharm, Beijing 100191, Peoples R China China Pharmaceut Univ, Sch Basic Med & Clin Pharm, Nanjing 211198, Peoples R China |
| Keywords | ANTHRACYCLINE-INDUCED CARDIOTOXICITY POPULATION PHARMACOKINETIC ANALYSIS VORICONAZOLE PLASMA-CONCENTRATION SINGLE NUCLEOTIDE POLYMORPHISMS ACUTE LYMPHOBLASTIC-LEUKEMIA RENAL-TRANSPLANT RECIPIENTS CONSORTIUM CPIC GUIDELINES VALPROIC ACID THERAPY GENE POLYMORPHISMS MYCOPHENOLATE-MOFETIL |
| Issue Date | Jan-2023 |
| Publisher | PEDIATRIC DRUGS |
| Abstract | As the activity of certain drug metabolizing enzymes or transporter proteins can vary with age, the effect of ontogenetic and genetic variation on the activity of these enzymes is critical for the accurate prediction of treatment outcomes and toxicity in children. This makes pharmacogenetic research in pediatrics particularly important and urgently needed, but also challenging. This review summarizes pharmacogenetic studies on the effects of genetic polymorphisms on pharmacokinetic parameters and clinical outcomes in pediatric populations for certain drugs, which are commonly prescribed by clinicians across multiple therapeutic areas in a general hospital, organized from those with the most to the least pediatric evidence among each drug category. We also further discuss the research status of the gene-guided dosing regimens and clinical implementation of pediatric pharmacogenetics. More and more drug-gene interactions are demonstrated to have clinical validity for children, and pharmacogenomics in pediatrics have shown evidence-based benefits to enhance the efficacy and precision of existing drug dosing regimens in several therapeutic areas. However, the most important limitation to the implementation is the lack of high-quality, rigorous pediatric prospective clinical studies, so adequately powered interventional clinical trials that support incorporation of pharmacogenetics into the care of children are still needed. |
| URI | http://hdl.handle.net/20.500.11897/669574 |
| ISSN | 1174-5878 |
| DOI | 10.1007/s40272-023-00560-3 |
| Indexed | SCI(E) |
| Appears in Collections: | 人民医院 药学院 |
